From the American Academy of Ophthalmology

This 24-month open-label extension of an earlier 12-month randomized phase 3 trial included 208 patients who received ranibizumab on the basis of prespecified retreatment criteria, guided by BCVA and disease progression. At the end of the extension study, ranibizumab was effective in improving or maintaining both BCVA and central retinal subfield thickness outcomes, with a progressively declining number of injections over three years of individualized dosing.  All patients received a mean of < 3 injections in the final year, while 19% to 25% of patients did not require any re-treatment during the extension study. Ophthalmology, May 2014